The abstract is read at the publisher; the summary is JClub's.
A single infusion of CRISPR/Cas9-edited Sca1+ HSPCs (mPPL-001) into myeloablative humanized YG8JR mice durably increases frataxin and corrects multisystem FRDA pathology.
- Why it matters: FRDA stems from GAA repeat expansion causing frataxin deficiency and mitochondrial dysfunction, yet existing treatments do not fix the genetic defect or systemic disease drivers.
- What they did: Ex vivo CRISPR/Cas9 excision of the GAA expansion in HSPCs was infused once into myeloablative humanized YG8JR mice, followed by assessment of engraftment, FXN expression, and inflammatory and mitochondrial readouts across tissues.
- The result: Donor-derived cells engrafted long-term across hematopoietic and FRDA-affected tissues, with corrected mitochondrial stress, microglial/macrophage activation, and inflammatory signaling, improving motor function, cerebellar structure, cardiac pathology, and survival of pancreatic insulin-producing β cells.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.